Information Provided By:
Fly News Breaks for December 10, 2019
GBT
Dec 10, 2019 | 05:29 EDT
Piper Jaffray analyst Danielle Brill raised her price target for Global Blood Therapeutics to $120 from $95 after speaking to a sickle cell disease key opinion leader. The stock closed Monday down $4.24 to $75.11. The analyst is "increasingly confident" in Oxbryta's launch and long-term trajectory, noting that the key opinion leader expects 10%-20% of his patients will go on drug within the first year of launch. Looking out five years from now, the leader anticipates that 40%-50% of the sickle cell disease population could be on drug, Brill tells investors in a research note. As such, she's "still pounding the table" on Global Blood shares and keeps an Overweight rating on the name.
News For GBT From the Last 2 Days
GBT
Aug 4, 2021 | 12:12 EDT
Get caught up quickly on the top news and calls moving stocks with these Top Fives, as compiled by the editors of The Fly.  1... To see the rest of the story go to thefly.com. See Story Here
GBT
Aug 4, 2021 | 09:59 EDT
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Camping World (CWH) upgraded to Outperform from Neutral at Baird with analyst Craig Kennison saying in an "extremely tight market," Camping World made the most of the inventory shortage to drive record profitability in Q2. 2. BJ's Restaurants (BJRI) upgraded to Buy from Hold at Deutsche Bank with analyst Brian Mullan saying the risk/reward "seems better now" with the stock down 39% from the March high. 3. Gaming and Leisure Properties (GLPI) upgraded to Buy from Neutral at UBS with analyst Robin Farley saying the shares should re-rate on the resilience of the company's tenants and strength of it leases. 4. Under Armour (UAA) upgraded to Overweight from Neutral at JPMorgan with analyst Matthew Boss seeing a favorable risk/reward setup following the stock's 75% underperformance relative to the retail sector over the past 18 months. 5. Global Blood Therapeutics (GBT) upgraded to Buy from Hold at Truist with analyst Joon Lee saying the company's Q2 results were "solid" and the quarter represents a "fundamental shift" for the stock. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
GBT
Aug 4, 2021 | 08:24 EDT
Truist analyst Joon Lee upgraded Global Blood Therapeutics to Buy from Hold with a price target of $50, up from $45. The company's Q2 results were "solid" and the quarter represents a "fundamental shift" for the stock, the analyst tells investors in a research note. With about 7K total patients prescribed and two commercial catalysts expected in the first half of FY22, shares of Global Blood Therapeutics will rebound after a year of underperformance, Lee adds.
GBT
Aug 4, 2021 | 05:13 EDT
Truist analyst Joon Lee upgraded Global Blood Therapeutics to Buy from Hold with a $50 price target.